Trials / Unknown
UnknownNCT02926300
Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)
Extension Study, An Open-labelled, Multi Center, Comparative Phase I/IIa Clinical Trials to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 24 (estimated)
- Sponsor
- Kang Stem Biotech Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical trial is to evaluate long-term safety and efficacy in patients who has history of FURESTEM-CD injection at least once.
Detailed description
This study is an extended study of KSTHD\_FURESTEM-CD phase 1 / 2a clinical trials in patients with moderate active Crohn's disease who had received at least once a FURESTEM-CD injection. The purpose of this clinical trial is to evaluate long-term safety and efficacy in patients for approximately 36 months (144 weeks).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | stem cells | IV infusion |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2021-10-01
- Completion
- 2021-11-01
- First posted
- 2016-10-06
- Last updated
- 2017-09-06
Locations
7 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02926300. Inclusion in this directory is not an endorsement.